Pipeline dossier

NIH & clinical-trial pipeline signals for Sanofi (SNY)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for SNY, mapped to public ticker SNY (CIK 0001121404). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingSNY55% conf

Sanofi (SNY) — PHASE2 primary completion in ~176 days

Upstream (observed)
Clinical trial status (PHASE2) — Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingSNY35% conf

Sanofi (SNY) — PHASE2 protocol updated 11 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

JSON API for this entity →